Sean Sheridan and Zlatina Dobreva discuss the importance of licensing intellectual property in the life sciences industry in the successful commercialization of early-stage therapeutics. Different licensing structures reflect the need for licensors and licensees to consider the range of paths for early-stage biotechnology development and then take all available and mutually agreeable steps to protect their interests. Read the full piece below.
Gene therapy competitive dynamics: Winner takes all?
This article was originally published in Cell & Gene. It has also been published in Cell & Gene‘s sister publication, OutSourced Pharama. With many gene...